Based on the recognition of IDH mutations as key disease-defining features of astrocytomas and oligodendrogliomas that reliably distinguish them from glioblastomas, assessment of the IDH status has become an integral part of the diagnostic algorithm for glioma classification. Here, IDH2 is linked to glioblastoma.